ATE333274T1 - Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii - Google Patents
Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ iiInfo
- Publication number
- ATE333274T1 ATE333274T1 AT02741155T AT02741155T ATE333274T1 AT E333274 T1 ATE333274 T1 AT E333274T1 AT 02741155 T AT02741155 T AT 02741155T AT 02741155 T AT02741155 T AT 02741155T AT E333274 T1 ATE333274 T1 AT E333274T1
- Authority
- AT
- Austria
- Prior art keywords
- biotin
- patients
- treatment
- diabetes mellitus
- acetylcarnitine
- Prior art date
Links
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 title abstract 4
- 206010022491 Insulin resistant diabetes Diseases 0.000 title abstract 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 title abstract 2
- 229960002685 biotin Drugs 0.000 title abstract 2
- 235000020958 biotin Nutrition 0.000 title abstract 2
- 239000011616 biotin Substances 0.000 title abstract 2
- 229960001009 acetylcarnitine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000294A ITRM20010294A1 (it) | 2001-05-29 | 2001-05-29 | Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE333274T1 true ATE333274T1 (de) | 2006-08-15 |
Family
ID=11455558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02741155T ATE333274T1 (de) | 2001-05-29 | 2002-05-24 | Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20040142879A1 (enExample) |
| EP (1) | EP1399142B1 (enExample) |
| JP (1) | JP4381685B2 (enExample) |
| KR (1) | KR20040010666A (enExample) |
| AT (1) | ATE333274T1 (enExample) |
| CA (1) | CA2448244C (enExample) |
| CY (1) | CY1105403T1 (enExample) |
| CZ (1) | CZ297743B6 (enExample) |
| DE (1) | DE60213237T2 (enExample) |
| DK (1) | DK1399142T3 (enExample) |
| ES (1) | ES2268053T3 (enExample) |
| HU (1) | HUP0400060A2 (enExample) |
| IT (1) | ITRM20010294A1 (enExample) |
| MX (1) | MXPA03010921A (enExample) |
| PL (1) | PL207522B1 (enExample) |
| PT (1) | PT1399142E (enExample) |
| SK (1) | SK287832B6 (enExample) |
| WO (1) | WO2002096410A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230002B1 (en) * | 2000-12-15 | 2015-04-28 | Sigma Tau Ind Farmaceuti | Use of l-carnitine for preparation of compositions for stabilizing the proteins |
| ITRM20040327A1 (it) * | 2004-07-01 | 2004-10-01 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici. |
| US8569366B2 (en) | 2005-04-26 | 2013-10-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes |
| EP1832295A1 (en) * | 2006-03-10 | 2007-09-12 | Tecnogen S.P.A. | Use of PTX3 for the treatment of viral diseases |
| ES2546619T3 (es) * | 2007-03-21 | 2015-09-25 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Composición útil para la prevención de la diabetes tipo 2 y sus complicaciones en pacientes pre-diabéticos con resistencia a la insulina |
| GB201304112D0 (en) * | 2013-03-07 | 2013-04-24 | Univ Nottingham | Modulation of energy expenditure |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1196564B (it) * | 1986-08-04 | 1988-11-16 | Sigma Tau Ind Farmaceuti | Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche |
| IT1263004B (it) * | 1992-10-08 | 1996-07-23 | Sigma Tau Ind Farmaceuti | Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti. |
| US6020139A (en) * | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| US5789401A (en) * | 1997-08-08 | 1998-08-04 | Nutrition 21 | High-dose chromium/biotin treatment of type II diabetes |
-
2001
- 2001-05-29 IT IT2001RM000294A patent/ITRM20010294A1/it unknown
-
2002
- 2002-05-24 PL PL367630A patent/PL207522B1/pl not_active IP Right Cessation
- 2002-05-24 HU HU0400060A patent/HUP0400060A2/hu unknown
- 2002-05-24 WO PCT/IT2002/000338 patent/WO2002096410A1/en not_active Ceased
- 2002-05-24 ES ES02741155T patent/ES2268053T3/es not_active Expired - Lifetime
- 2002-05-24 MX MXPA03010921A patent/MXPA03010921A/es active IP Right Grant
- 2002-05-24 CA CA2448244A patent/CA2448244C/en not_active Expired - Fee Related
- 2002-05-24 CZ CZ20033221A patent/CZ297743B6/cs not_active IP Right Cessation
- 2002-05-24 US US10/478,372 patent/US20040142879A1/en not_active Abandoned
- 2002-05-24 SK SK1585-2003A patent/SK287832B6/sk not_active IP Right Cessation
- 2002-05-24 EP EP02741155A patent/EP1399142B1/en not_active Expired - Lifetime
- 2002-05-24 JP JP2002592920A patent/JP4381685B2/ja not_active Expired - Fee Related
- 2002-05-24 PT PT02741155T patent/PT1399142E/pt unknown
- 2002-05-24 DK DK02741155T patent/DK1399142T3/da active
- 2002-05-24 KR KR10-2003-7015575A patent/KR20040010666A/ko not_active Ceased
- 2002-05-24 AT AT02741155T patent/ATE333274T1/de active
- 2002-05-24 DE DE60213237T patent/DE60213237T2/de not_active Expired - Lifetime
-
2006
- 2006-09-25 CY CY20061101375T patent/CY1105403T1/el unknown
-
2008
- 2008-07-02 US US12/216,279 patent/US8053472B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK1399142T3 (da) | 2006-10-30 |
| WO2002096410A1 (en) | 2002-12-05 |
| CZ20033221A3 (cs) | 2004-06-16 |
| KR20040010666A (ko) | 2004-01-31 |
| US20080269307A1 (en) | 2008-10-30 |
| ITRM20010294A0 (it) | 2001-05-29 |
| ITRM20010294A1 (it) | 2002-11-29 |
| MXPA03010921A (es) | 2004-02-27 |
| SK15852003A3 (sk) | 2004-04-06 |
| ES2268053T3 (es) | 2007-03-16 |
| CA2448244A1 (en) | 2002-12-05 |
| US20040142879A1 (en) | 2004-07-22 |
| PT1399142E (pt) | 2006-10-31 |
| EP1399142B1 (en) | 2006-07-19 |
| CY1105403T1 (el) | 2010-04-28 |
| PL207522B1 (pl) | 2010-12-31 |
| HUP0400060A2 (hu) | 2004-04-28 |
| JP4381685B2 (ja) | 2009-12-09 |
| EP1399142A1 (en) | 2004-03-24 |
| CZ297743B6 (cs) | 2007-03-21 |
| JP2004532866A (ja) | 2004-10-28 |
| DE60213237T2 (de) | 2007-08-02 |
| DE60213237D1 (de) | 2006-08-31 |
| CA2448244C (en) | 2010-11-02 |
| SK287832B6 (sk) | 2011-11-04 |
| US8053472B2 (en) | 2011-11-08 |
| PL367630A1 (en) | 2005-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE495739T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| DE602005020269D1 (de) | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren | |
| DE60225331D1 (de) | Pharmazeutische zusammensetzungen mit metformin und glibenclamid zur behandlung von diabetes mellitus typ ii | |
| UY27787A1 (es) | Activadores cicloalquil sustituidos y cicloalquil oxigenados de glucoquinasa. | |
| DK1349856T3 (da) | Isoindolin-1-on-glucokinase-aktivatorer | |
| EA200501095A1 (ru) | Фенилацетамиды и их применение в качестве модуляторов глюкокиназы | |
| DE60328517D1 (de) | Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung | |
| DE60227718D1 (de) | Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen | |
| ATE548032T1 (de) | Verwendung von chlorguanabenzderivaten zur behandlung von mit polyglutaminexpansion assoziierten erkrankungen | |
| ATE234615T1 (de) | Verwendung von acetylcystein zur herstellung eines arzneimittels zur behandlung von chronischen geschwüren | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| ATE289816T1 (de) | Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen | |
| ATE333274T1 (de) | Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii | |
| DE60239670D1 (de) | Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| DE60118769D1 (de) | Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten | |
| DE60305279D1 (de) | Verwendung von Methyltestosteron zur Behandlung von menschlichen Papillomavirus Infektionen | |
| ATE354361T1 (de) | Neue verwendung von prodigiosin zur behandlung von diabetes mellitus | |
| ATE382054T1 (de) | Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis | |
| ATE239492T1 (de) | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen | |
| DE69930419D1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie | |
| DE50207110D1 (de) | Kombinationspräparat zur behandlung des diabetes mellitus | |
| ATE374021T1 (de) | Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post- chirurgischen schmerzbehandlung | |
| DE60216090D1 (de) | Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia | |
| ATE454897T1 (de) | Verwendung von winterbohnenkraut (satureja montana) oder seinen extrakten zur herstellung von medikamenten zur behandlung von vorzeitiger ejakulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1399142 Country of ref document: EP |